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Background: Antiretroviral therapy (ART) has improved lifespan and quality of life 
of patients infected with the HIV-1. However, ART has several potential limitations, 
including the development of drug resistance and suboptimal penetration to selected 
anatomic compartments. Improving the delivery of antiretroviral molecules could 
overcome several of the limitations of current ART. Results & Conclusion: Two to 
ten nanometer diameter inorganic gold crystals serve as a base scaffold to combine 
molecules with an array of properties in its surface. We show entry into different cell 
types, antiviral activity of an HIV integrase inhibitor conjugated in a gold nanoparticle 
and penetration into the brain in vivo without toxicity. Herein, gold nanoparticles 
prove to be a promising tool to use in HIV therapy.
The introduction of antiretroviral 
therapy (ART) into clinical practice in the 
1990’s led to a huge improvement in the life 
expectancy and quality of life of HIV-infected 
persons. During the first years of antiretro-
viral treatment, when only a few antiretro-
viral drugs were available, <40% of treated 
patients achieved virologic suppression after 
a year of treatment [1]. Currently, 31 antiret-
roviral drugs are approved for the treatment 
of HIV infection, and virologic success rate 
is usually >80%, even when drug resistance 
is present [2].
However, a cure for HIV infection has not 
yet been described, and so lifelong antiret-
roviral treatment is needed by many, entail-
ing risks of the emergence of drug resistance, 
long-term drug toxicities and loss of adherence 
to therapy over time. In addition, antiretrovi-
ral drugs fail to penetrate in certain tissues, 
allowing the creation of viral reservoirs. 
Thus, despite all the benefits that ART 
confers, improvements in ART can be made.
Nanomedicine is a promising area of bio-
technology full of possibilities for novel ther-
apeutics. Nanoparticles are primarily charac-
terized by their size, in the nanometer range. 
This small size confers unique chemical 
and physical properties, useful in imaging, 
diagnosis and therapy. Several nanoparticle 
systems have already been approved for clini-
cal use, primarily liposomal drugs and poly-
mer-drug conjugates [3]. For HIV therapy, the 
existing HIV antiretroviral drugs indinavir, 
zidovudine and saquinavir have undergone 
nanoformulation for testing in vitro systems 
and preclinical animal models [4]. Antiretro-
viral drug combinations have also been nano-
formulated, such as efavirenz, atazanavir and 
ritonavir [5], and efavirenz, lopinavir and rito-
navir [6]. Both demonstrated robust antiviral 
effect and improved bioavailability.
Recently, we have become interested in 
the application of small molecule-conjugated 
inorganic nanoparticles, gold in particular, 
to generate potentially new therapeutics for 
the treatment of infectious diseases. In the 
present study, we tested gold nanoparticles 
(AuNPs) for the treatment of HIV.
Gold nanoparticles have already been 
used in gene and cancer targeting, imaging 
and delivery of therapeutics [7–10], reaching 
clinical trials for cancer patients [11]. Several 
characteristics make AuNPs highly attractive 
for clinical use, such as their small size that 
facilitates entry into tissues and cells, their 
inert nature that insures little host response 
to the molecules, and their potential for 
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multivalency which allows the simultaneous conju-
gation of different molecules in the nanoparticle sur-
face and the simultaneous delivery of these payloads. 
Herein, we study the capacity of AuNPs to enter into 
different cell types, cross the blood–brain barrier 




P-mercaptobenzoic acid (pMBA) coated AuNPs 
were synthesized according to our previous publica-
tions [12,13]. A solution of 20 mM HAuCl
4
 (Strem, 
MA, USA) dissolved in 20 ml of methanol was com-
bined with 85.0 mM pMBA dissolved in pH 12 ultra-
pure water. Gold mixtures were allowed to equilibrate 
for 15 min while stirring. The solutions (0.40 mmol 
of Au3+) were diluted to a final Au3+ concentration of 
0.55 mM with the addition of 202 ml of ultrapure 
water and 186 ml of methanol. The Au3+ was reduced 
with 7.2 ml of a 0.25 M aqueous sodium borohydride 
(Sigma-Aldrich, MO, USA) solution. The reduction 
was allowed to proceed for 24 h at room tempera-
ture with constant stirring. Gold nanoparticles were 
precipitated with the addition of 120 mmol of NaCl 
in 720 ml of methanol followed by centrifugation at 
3200 × g RCF for 5 min. Precipitated nanoparticles 
were reconstituted in water.
The concentration was measured by UV-visi-
ble spectroscopy using the extinction coefficient of 
400,000 M-1 cm-1 at 510 nm.
Place-exchange of ligands to AuNPs
One pot place exchange reactions were conducted with 
the addition of varying concentrations of ligand of 
interest – raltegravir, Cy5, TAMRA or glucose – to 
a 10 μM concentration of AuNPs in 20 mM sodium 
phosphate buffer, pH 9.5. Reactions were placed on a 
plate shaker and agitated for 24 h at room temperature. 
The exchange product was harvested through the addi-
tion of 40 mmoles of NaCl and a volume of methanol 
equal to that of phosphate buffer and added salt. Reac-
tions were centrifuged at 3200 × g RCF for 30–60 min. 
Precipitated nanoparticles were resuspended and pre-
cipitated with the addition of NaCl and methanol 
2-times to wash out excess unreacted thiol. Particles 
were allowed to dry to completion overnight at room 
temperature and resuspended in 20 mM sodium phos-
phate buffer, pH 9.5. Resuspended nanoparticles were 
washed with 20 mM sodium phosphate buffer, pH 9.5 
over a 30K MWCO centricon filter to remove excess salt 
and thiol. The final concentrations were determined by 
UV-visible spectroscopy as described above.
Characterization of AuNPs
Transmission electron microscopy
Transmission electron microscopy (TEM) grids were 
prepared by placing a drop of the AuNPs on a carbon 
film covered copper mesh grid for a minute, and then 
excess solution was wicked away with a paper filter. 
Grids were then allowed to air-dry for 45 min before 
being imaged by TEM. The subsequent TEM images 
were analyzed by Image-J (National Institutes of 
Health, MA, USA) to determine the size distribution 
of the AuNP cores. A minimum of 100 particles was 
measured before analysis of size distribution.
Analysis of place-exchange ratios
The success of place-exchange was measured using our 
previous methods [13] for UV-vis with no exceptions. 
Measurements were recorded at wavelengths of 260 
and 510 nm.
In vitro cellular uptake & toxicity of AuNPs
Immunohistochemistry
Uptake of AuNPs was evaluated in peripheral blood 
mononuclear cells (PBMCs), macrophages and human 
brain microendothelial cells (HBMECs). PBMCs 
were obtained by Ficoll gradient centrifugation, and 
macrophages were selected by adherence to plastic. 
HBMECs were primary cell lines obtained by elutria-
tion of dispase-dissociated normal human brain cortex 
tissue (Cell-Systems, WA, USA).
PBMCs and macrophages were incubated for 24 h 
with 500 nM AuNPs conjugated with Cy5 or TAMRA 
in Iscove’s Modified Dulbecco’s Media (IMDM) sup-
plemented with penicillin/streptomycin, 10% fetal 
bovine serum (FBS) and 5 U/ml recombinant IL-2 
(Peprotech, NJ, USA). HBMECs were incubated for 
Key terms
Antiretroviral therapy: Combination of three or more 
drugs used to treat HIV infection and suppress viral 
replication. Drugs target different steps in the viral cycle 
to inhibit them, such as viral entry, retrotranscription, 
integration and maduration.
HIV: Causal agent of the AIDS. 
Viral reservoir: Cell or anatomical site where a replication-
competent viral genome persists in a latent state from 
which can be reactivated and produce virions. 
Blood–brain barrier: Selective permeability barrier which 
separates the central nervous system from the circulating 
blood. It is comprised by capillary endothelial cells 
connected by tight junctions.
Raltegravir: First in class of the family of antiretrovirals 
inhibiting the integrase of the HIV. Specifically inhibits the 
strand transfer step within integration of the viral genome 
in the host chromosome. Marketed by Merck and first 
approved by the US FDA in 2007.
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24 h with 100 nM AuNPs conjugated with TAMRA 
in CSC Complete Medium (Cell-Systems, WA, USA) 
with 10% FBS. Cells were then washed 3-times with 
phosphate buffered saline (PBS) and stained to allow 
nuclei visualization with Hoechst 33342 (ThermoSci-
entific, IL, USA) or DAPI (Molecular Probes, Invit-
rogen, CA, USA). In addition, cells were stained with 
CellMask Orange plasma membrane stain (Molecu-
lar Probes, Invitrogen, Carlsbad, CA) to allow mem-
brane visualization. HBMECs were stained with 
anti-B-catenin (Sigma-Aldrich) instead of CellMask 
to visualize tight junctions. After washing with PBS, 
cells were plated in chambered cover glasses (Lab-Tek, 
Thermo Fisher Scientific, Inc., Roskilde, Denmark) 
and imaged by confocal laser scanning microscopy 
(Olympus FV1000 Multiphoton Confocal, Olympus 
America, PA, USA), using the 60× objective.
Flow cytometry
PBMCs were incubated with IMDM supplemented 
with penicillin/streptomycin, 10% FBS and 5 U/ml 
IL-2 during 2 days. Gold nanoparticles conjugated 
with Cy5 at different concentrations (0, 1 and 3 μM) 
were added to the plates and harvested after 6 and 24 h. 
Samples were washed twice with PBS 2% FBS and then 
stained with Live/Dead Fixable Aqua Dead Cell Stain 
(Molecular Probes, Invitrogen, NY, USA) following 
manufacturer’s instructions. Flow cytometry was per-
formed using BD LSR Fortessa equipped with FACS-
DIVA software. PBMCs were gated by forward scatter 
versus sideward scatter (FSC/SSC) plots, and gated on 
the viable population according to Aqua Dead Cell 
staining, selecting the negative fraction. Nanoparticle 
uptake was quantified on this viable population by Cy5 
fluorescence.
To further analyze cell toxicity, we incubated CD8-
depleted PBMCs with increasing concentrations of 
AuNPs conjugated with raltegravir or AuNPs alone 
for 24, 48 and 72 h. We selected CD8-depleted cells 
because HIV inhibition assays are performed in this 
cell population, given that CD8 cells naturally secrete 
antiviral factors and exert considerable antiviral activ-
ity. Thus, it was important to assess safety particularly 
in CD8-depleted cells. After the different incubation 
times, cells were harvested and stained with FITC-
Annexin V and 7AAD (Biolegend, CA, USA) and 
analyzed by fluorescence-activated cell sorter (FACS). 
We considered cells positive for both Annexin V and 
7-AAD as the dead population, without differentiating 
degrees of apoptosis/necrosis.
In vivo delivery of AuNPs to the brain
Female adult BALB mice were used to analyze the 
distribution of the AuNPs in vivo. All animal work 
was approved by the University of North Carolina 
Institutional Animal Care and Use Committee.
Gold nanoparticles were diluted in 200 μl PBS at a 
concentration of 30 μM to be injected into the tail vein of 
each of three mice. In addition, a mouse was used as nega-
tive control and was injected with a PBS solution without 
nanoparticles. After 24 h, animals were humanely eutha-
nized, and tissues were harvested. Organs were collected 
in PBS, weighed and digested with nitric acid (Optima, 
Fisher Scientific, Roskilde, Denmark) overnight. Sam-
ples were heated until all acid had evaporated, and tissues 
were resuspended in water, sonicated to eliminate any 
remaining tissue and analyzed using inductively coupled 
plasma – optical emission spectroscopy [14] to quantitate 
the gold content. The same procedure was performed 
using AuNPs conjugated with glucose.
ICP-MS analysis
Analysis of gold content in biological samples was per-
formed using a Perkin-Elmer SCIEX ICP-MS (model 
Elan DRC-e, IL, USA) at the University of Colorado 
Laboratory for Environmental and Geological Sci-
ences. Statistical analysis of samples was performed as 
described in Simpson et al. [15] involving the student’s 
t test (95% confidence level), but with units in μg/ml. 
The detection limit of the instrument was 0.02 ppb 
(0.02 ng Au/ml) sample.
HIV inhibition with AuNPs conjugated with 
raltegravir
Raltegravir (RAL) was modified with the incorporation 
of a thiol group to serve as linker to a gold nanopar-
ticle, designated EL-04–109 or thiolated raltegravir 
(Figure 1). Gold nanoparticles were conjugated to differ-
ent number of molecules of this RAL derivative, making 
particles with 4 (4:1), 33 (33:1) and maximal numbers 
(60:1) of EL-04–109 RAL derivative molecules. CD8-
depleted PBMCs from a healthy donor were stimulated 
with 2 μg/ml phytohematoglutinin (Remel, KS, USA) 
and 60 U/ml of IL-2 for 24 h. Drugs were diluted to 
different concentrations and added to the cells in tripli-
cate. Finally, cells were infected with the R5 tropic HIV 
strain JRCSF (16 pg p24/106 cells). Supernatants were 
harvested at day 5 and HIV-1 capsid p24 antigen was 
measured by ELISA (ABL, MD, USA).
Raltegravir derivatives synthesis
Detailed explanation of raltegravir derivatives synthesis 
can be found in the Supporting Material section.
Results
Characterization of the AuNPs
The diameter of the pMBA-Au nanoparticles was 
1.8 ± 0.32 nm as determined by TEM. This size is 
Figure 1. Modified raltegravir molecule, EL-04–109 
(thiolated raltegravir). Chemical formula: C27H35N7O6S. 
















Figure 2. Transmission electron microscopy image of 
gold-p-mercaptobenzoic acid nanoparticles. Particles 
displayed an average diameter of 1.8 ± 0.32 nm.
20 nm
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similar to pMBA-Au nanoparticles characterized by 






For the HIV inhibition assays, AuNPs were con-
jugated with different numbers of thiolated raltegra-
vir molecules, resulting in particles with 4, 33 and 
complete coverage (60).
Cellular uptake & toxicity of AuNPs
Cellular uptake of fluorescence-labeled nanoparticles was 
qualitatively evaluated by confocal laser scanning micros-
copy. Gold nanoparticles were conjugated with Cy5 or 
TAMRA (AuNP-Cy5 or AuNP-TAMRA, respectively) 
and incubated with different cell types – PBMCs, mac-
rophages and HBMECs – to evaluate cellular uptake. 
Confocal microscopy imaging showed nanoparticles 
inside all the three cell types after 24 h (Figure 3). Fluo-
rescence was observed widely in the cytoplasm of all the 
cells, but signal in the nucleus was much weaker. 
To determine more accurately the uptake kinetics 
and to evaluate cell toxicity, PBMCs were incubated 
with increasing concentrations of AuNP-Cy5 and 
analyzed with FACS at different time points. FACS 
data indicated AuNPs cellular uptake in a dose–time 
dependent way (Figure 4). We observed a gradual 
increase in the intensity of Cy5 in the viable cell popu-
lation, reaching 54% after 24 h incubation with 3 μM 
nanoparticles. This indicates a progressive cellular 
uptake of the nanoparticles. In addition, after incubat-
ing PBMCs with different concentrations of AuNPs 
conjugated or not with raltegravir, a complete lack of 
toxicity was observed at 24, 48 and 72 h (Figure 5).
In vivo delivery to the brain
Three mice were injected via tail vein with nanoparti-
cles at a concentration of 30 μM. After 24 h, mice were 
sacrificed and tissues were extracted for gold quantifi-
cation by inductively coupled plasma–mass spectrom-
etry (ICP-MS). ICP-MS gold measurements revealed 
that the majority of nanoparticles accumulate in the 
spleen, reaching up to 28% of the injected material per 
gram of tissue in one of the mice. Au was also found 
in liver, kidneys, lung, tail, heart, brain and blood 
(Table 1). To increase nanoparticle transport across the 
BBB, we conjugated glucose to the AuNPs, given that 
BBB express Glut-1 receptor, which mediates glucose 
transport. Average brain content of Au was 333.6 ng/g 
of tissue, and it did not differ between mice injected 
with AuNP-TAMRA and AuNP-glucose (347 vs 
320 ng/g tissue, respectively). However, upon conjuga-
tion of glucose to the nanoparticles, accumulation into 
the spleen seemed to decrease (34,356 vs 15,074 ng/g 
tissue in the AuNP and AuNP-glucose, respectively).
HIV inhibition with AuNPs conjugated with 
raltegravir
Gold nanoparticles were conjugated with molecules of 
raltegravir and HIV inhibition was tested in infected 
primary PBMCs depleted from CD8+cells. As shown in 
Figure 6A, at day 5, AuNPs conjugated with four mol-
ecules of raltegravir (RAL-AuNP 4:1) inhibited HIV-1 
replication down to 25.23%. Interestingly, increasing 
the number of RAL molecules into each gold particle did 
not improve antiviral performance but rather impaired 
it, as shown when tested 33:1 or 60:1 (RAL:AuNP). As 
with our previous work [13], it is important to note the 
lack of antiviral activity of free modified raltegravir, due 
to the alteration of its structure, and that activity was 
restored when the molecule was conjugated to the gold 
particle. Commercial raltegravir, used as positive control, 
Figure 3. Confocal images of different cell types incubated with gold nanoparticles-tetramethylrhodamine 
or gold nanoparticles-Cy5 (red) for 24 h at 37°C on glass coverslips and fixed before mounting. Nuclei were 
stained with 4’,6-diamidino-2-phenylindole or Hoechst 33342 (blue). Transmitted light overlay, Cell Mask stain or 
β-catenin (green) shows the delimited plasma membrane for each cell type. Images are from a representative view 
of the whole picture and from one of the at least three experiments performed. 
AuNP: Gold nanoparticle; HBMC: Human brain microendothelial cell; PBMC: Peripheral blood mononuclear cell; 
TAMRA: Tetramethylrhodamine.  
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Figure 4. Cy5 intensity measured by FACS after 
peripheral blood mononuclear cells were exposed for 
6 or 24 h to gold nanoparticles-Cy5. Peripheral blood 
mononuclear cells were derived from one healthy 
donor. Cell-associated fluorescence was evaluated 
using FACS analysis, gating on the viable population. A 
steady increase over time in the associated fluorescence 
was observed and it was also concentration dependent. 



















Time of exposure (h)
Figure 5. Cell viability measured by FACS after 24, 48 and 72 h incubation with raltegravir, gold nanoparticle or 
gold nanoparticle-raltegravir at different concentrations (0, 50, 500 and 1000 nM). Peripheral blood mononuclear cells were derived 
from one healthy donor. Graph represents percentage of peripheral blood mononuclear cells positive for both annexin V and 
7-aminoactinomycin D, and as shown, viability is not compromised by culture with the different nanoparticles in this 3-day period. 
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inhibited viral replication at lower concentrations. We 
also tested the impact of AuNPs without RAL conjuga-
tion on HIV replication in an independent experiment. 
As shown in Figure 6B, AuNPs themselves did not have 
a significant effect on HIV replication, and thus we con-
firm that the effect observed with AuNP-RAL molecules 
is caused by the addition of RAL to the gold core.
Discussion
Nanotechnology is a novel and promising tool for 
diagnosis and treatment in medicine. Different materi-
als such as dendrimers, liposomes, synthetic polymeric 
nanoparticles, micelles or inorganic substances (iron 
oxide, quantum dots, gold and silica) can be fabricated 
for use in nanoscale.
Here, we have studied the properties of AuNPs to 
assess their potential use for HIV therapy. We have 
proven that AuNPs can be conjugated to different mol-
ecules and penetrate into cells. They can also cross the 
BBB allowing the transport of molecules to the brain. 
Moreover, cell viability assays showed that these AuNPs 
did not cause short-term cell toxicity and that they can 
be conjugated to an antiviral molecule and retain anti-
viral activity. We have previously demonstrated the 
latter with an antiviral nanoparticle that acted outside 
of the cell, blocking viral entry [13], but here we demon-
strate the activity of an antiviral nanoparticle that acts 
inside the cell, which is of importance given that many 
drugs need to be inside the cell to exert their activ-
ity. Such capabilities have been individually shown for 
nanoparticles [13,15,16], but this is the first demonstra-
tion of a multifunctional AuNP. These results sup-
port continued studies of AuNPs as scaffolds for the 
delivery of therapeutic molecules.
In the present work, we first tested the ability of AuNPs 
to enter different cell types. Cellular uptake efficiency 
depends on both characteristics of the nanoparticle, such 
as size, shape and charge of the surface, and properties 
of the cell, such as the cell cycle state [17]. Additionally, 
cellular uptake and partitioning into cellular organelles 
and domains (e.g., nuclear vs cytoplasmic) can each dif-
fer between cell types [18]. We investigated nanoparticle 
entry into different cells types, but focused on entry into 
lymphocytes, as this is the principal cell type involved in 
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HIV infection. Using fluorophore-conjugated nanopar-
ticles, we observed by confocal microscopy that nanopar-
ticles could enter not only into lymphocytes but also into 
other cell types of potential importance in HIV disease, 
such as macrophages and brain microendothelial cells. 
Mechanism of entry into the different cells types might 
differ [19]. Entry into macrophages would be expected to 
occur at least in part via phagocytosis, while entry into 
lymphocytes may occur via direct entry or pinocytosis. 
Particles were widely observed in the cytoplasm, but 
partition into the nucleus was often reduced. Although 
for many applications cytoplasmic delivery is sufficient, 
nuclear entry will be required for others. Nanoparticle 
size is important for entry into the nucleus, as the size 
of the nuclear pore does not exceed 45 nm [20]. Gold 
nanoparticles such as those used in this study can be fab-
ricated at diameters of approximately 2 nm. However, if 
facilitated entry into the nucleus is required, this might 
be achieved by attaching nuclear entry or targeting sig-
nals such as peptides from the SV40 large T antigen [21] 
or the HIV Tat peptide [22].
In theory, the in vivo administration of AuNPs 
might elicit toxicity and immunogenicity [23]. Thus, 
it is essential to evaluate their safety. Previous studies 
have demonstrated AuNPs are well tolerated in vivo [15], 
and in vitro toxicity may be primarily related to moi-
eties attached to the nanoparticle, rather than the gold 
particle itself [12,13,18,24–26]. Here, when administered 
to mice, no symptoms of toxicity were seen over 24 h. 
In vitro toxicity was preliminarily evaluated by measur-
ing a marker of early apoptosis over 3 days of exposure, 
and we found no evidence of toxicity.
The use of nanoparticle drug delivery systems to 
improve the efficiency of delivery of antiretroviral 
drugs such as saquinavir [27,28], atazanavir [29] and even 
a combination of different antiretroviral drugs [5,6] 
have been reported. However, these systems simply 
encapsulated the unmodified drugs inside particles, for 
improved cellular delivery.
Very few approaches using AuNPs as carrier for 
anti-HIV drugs have been reported [30,31]. Our groups 
tested in a previous work that AuNPs conjugated to 
a CCR5 antagonist, reduced viral production [13]. 
However, given the mechanism of action of CCR5 
antagonists, that is, viral entry inhibition, it was not 
demonstrated that nanoparticles could enter into the 
cell and exert antiviral activity. In the present study, 
we conjugated AuNPs with a modified form of ralte-
gravir that was only active when conjugated to gold. 
By thiolating the compound, we introduce a steric hin-
drance that cripples the compound as a single molec-
ular entity. However, once placed on a particle, the 
multivalent effect overcomes this penalty and delivers 
a viable entity. Thus, we could presume that a mul-
tivalent interaction is necessary that is not possible 
with the monomeric thiolated raltegravir but is present 
with the nanoparticles. The ability of these particles to 
inhibit HIV replication implies that these AuNPs enter 
the cell to exert antiviral effect. Interestingly, attaching 
a larger number of RAL molecules to the gold core, did 
not increase viral inhibition, as particles displaying 33 
RAL molecules or more actually possessed less anti-
viral activity than nanoparticles carrying only 4 RAL 
molecules. Many possible explanations for this attenu-
ation of effect require further study, but it is possible 
that as the coverage of raltegravir on the nanoparticles 
increases, molecular gathering hinders interaction with 
the target by unavoidable van der Waals interactions.
HIV penetrates into the CNS and can cause 
neurocognitive disorders, even in the presence of 
antiretroviral treatment [32]. In addition, it has been 
shown that the CNS can act as an HIV reservoir [33], 
Table 1. Gold content in different mouse tissues 24 h after 30 μM gold nanoparticle tail injection 
(three different mice per condition). 
Tissue AuNP, μg/g (SD) AuNP-glucose, μg/g (SD) 
Spleen 34.356 (1.112) 15.074 (2.548)
Liver 6.991 (1.810) 5.353 (2.476)
Kidney 5.934 (1.671) 4.910 (1.744)
Tail 4.508 (2.077) 2.830 (0.738)
Lungs 1.985 (0.260) 1.967 (0.191)
Heart 3.028 (0.022) 1.513 (0.284)
Brain 0.347 (0.050) 0.320 (0.131)
Muscle 0.867 (0.400) 0.083 (0.083)
Blood 1.993 (0.167) 3.062 (0.345)
Gold content was measured by inductively coupled plasma-MS. AuNPs tend to accumulate in spleen and liver, probably due to 
reticuloendothelial system clearance. Glucose conjugation did not change the distribution profile. 
AuNP: Gold nanoparticle.
Figure 6. Percentage of HIV replication measured by HIV p-24 ELISA at day 5 of culture in HIV-infected  
CD8-depleted peripheral blood mononuclear cells derived from one healthy donor. 100% corresponds to the viral 
replication observed in the absence of any drug (mean ± standard error of the mean). (A) AuNPs were conjugated 
with RAL at different ratios RAL:Au particle (4:1, 33:1, 60:1). After 5 days of culture with infected CD4+T cells, 
AuNP-RAL were able to inhibit viral replication to 25%. (B) AuNPs without raltegravir conjugation were tested to 
analyze their antiviral activity at different concentrations (500–4 nM). After 5 days of culture with infected CD4+ 
T cells, no significant viral inhibition was observed in the presence of AuNPs. 
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and thus, an important aim of our project was to 
improve drug delivery into the brain through the use 
of AuNPs. In this, we met only limited success. Pre-
vious studies have shown a relationship between par-
ticle size and biodistribution in murine models [34,35]. 
Intravenous administration of AuNPs of different sizes 
revealed a differential distribution among tissues, show-
ing that smaller nanoparticles (i.e., 15 nm) were more 
broadly distributed than larger ones (i.e., 200 nm). 
As the nanoparticles increased their size, an increase 
in spleen accumulation and decrease in brain concen-
tration was particularly observed. Thus, particle size 
has shown to be a factor in brain penetration, and we 
expected nanoparticles below 10 nm to enter the CNS 
more efficiently. However, in the mouse experiments 
we performed, AuNPs were predominantly found in 
spleen and only present in the brain at modest concen-
trations. Nanoparticles were capped with mercapto-
benzoic acid, which enlarged their size somewhat, and 
may have impaired CNS penetration to some extent. 
The substantial distribution of AuNPs into the spleen 
was not surprising given the phagocytic function of 
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this reticuloendothelial system (RES) organ, whose 
function is to remove foreign substances from the body. 
Some modifications can be made to the surface of the 
nanoparticles to protect them from RES clearance. 
The most widely used strategy is to coat the surface 
of the particle with surfactants such as polysorbate-80 
or albumin [36,37]. In order to reduce RES sequestra-
tion, we conjugated polyethyleneglycol to particles, 
to prolong their circulation time [38]. However, add-
ing polyethyleneglycol of different lengths (data not 
shown) did not increase brain penetration or decrease 
spleen uptake. The transport of AuNPs across the BBB 
might occur through different mechanisms: transcel-
lular lipophilic diffusion, transporter mediated tran-
scytosis, paracellular hydrophilic diffusion, receptor 
mediated endocytosis or absorptive mediated endo-
cytosis [39]. If transport takes place through receptor 
or transporter mediated endocytosis, we hypothesized 
that attaching a molecule that naturally crosses the 
BBB through specific receptors would help internal-
izing the whole nanoparticle complex. We conjugated 
glucose to the nanoparticles, but no improvement was 
observed. Finally, we conjugated a targeting peptide 
to try to direct nanoparticle delivery to the brain, but 
again we did not observe enhanced brain penetration. 
However, even if we did not manage to improve CNS 
penetration through any of the interventions, AuNPs 
were consistently found in the brain, proving that they 
are able to cross the BBB. More invasive approaches 
have been proposed to increase drug permeability 
through the BBB, such as inducing changes in the per-
meability of the BBB by modifying the osmotic pres-
sure [40] or disrupting the BBB with ultrasound [41]. 
However, such approaches carry with them clinical 
risks that are not acceptable, at least in the area of 
antiretroviral therapy.
Conclusion 
In summary, we have demonstrated delivery of a small 
molecule-conjugated AuNP into the cell types in 
which HIV might replicate, and shown antiviral activ-
ity in HIV infected primary lymphocytes. We have 
also demonstrated delivery of gold particles into the 
CNS in an in vivo model, although entry is subopti-
mal. This leaves important future possibilities for the 
translational development of this technology, as the 
delivery of multiple therapeutic moieties on a single 
nanoparticle is technically feasible. Future advances 
could include antiviral particles that carry CNS-tar-
geting molecules, or other molecules with novel or 
useful function.
Future perspective
The present study proposes the use of AuNPs to deliver 
antiretroviral drugs for HIV treatment. Here we dem-
onstrate the ability of AuNPs to be conjugated to dif-
ferent molecules, such as raltegravir, and exert antiviral 
effect inside the cell. Next steps will include conjugat-
ing several different molecules to the AuNPs, allow-
ing for simultaneous delivery of different therapeutics 
in the site of action, as well as evaluating the cellular 
uptake of AuNPs conjugated with different number 
and type of molecules.
Supplementary data
To view the supplementary data that accompany this paper 
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Executive summary
•	 Synthesis of gold nanoparticles (AuNPs) with a size of 2–10 nm which can be conjugated to different 
molecules.
•	 AuNPs conjugated to fluorophores enter into peripheral blood mononuclear cells, macrophages and human 
brain microendothelial cells.
•	 AuNPs can reach the brain after vein tail injection in mice.
•	 AuNPs can be conjugated to an antiretroviral drug, raltegravir, and exert antiviral activity inside the cells.
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